SecSonar.com

Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Maze Therapeutics, Inc. (MAZE) is a Biotechnology company based in US with a market capitalization of $1.5B. Free cash flow was negative at -$112.7M. This page tracks MAZE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 125 employees · IPO Jan 31, 2025

Valuation

Valuation & price

$25.56 · as of May 17, 2026 · -50.7% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

4.15

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$51.84$31.98$12.12Jul 25Dec 25Jul 26Jul 7, 25$12.12Jul 9, 25$15.08Jul 11, 25$15.05Jul 15, 25$16.01Jul 17, 25$17.06Jul 21, 25$16.66Jul 23, 25$17.64Jul 25, 25$16.82Jul 29, 25$15.74Jul 31, 25$14.75Aug 4, 25$15.25Aug 6, 25$14.25Aug 11, 25$13.47Aug 13, 25$13.60Aug 15, 25$13.50Aug 19, 25$13.45Aug 21, 25$13.23Aug 25, 25$13.31Aug 27, 25$13.87Aug 29, 25$14.49Sep 3, 25$15.19Sep 5, 25$15.88Sep 9, 25$16.34Sep 11, 25$24.80Sep 16, 25$23.46Sep 18, 25$23.48Sep 22, 25$23.67Sep 24, 25$26.18Sep 26, 25$27.00Sep 30, 25$25.93Oct 2, 25$26.50Oct 6, 25$27.52Oct 8, 25$28.60Oct 10, 25$27.43Oct 14, 25$28.50Oct 16, 25$28.45Oct 21, 25$29.52Oct 23, 25$29.90Oct 27, 25$31.00Oct 29, 25$31.26Oct 31, 25$32.91Nov 4, 25$32.42Nov 6, 25$29.63Nov 10, 25$30.49Nov 12, 25$32.56Nov 14, 25$32.53Nov 18, 25$33.23Nov 20, 25$35.57Nov 25, 25$36.70Nov 28, 25$37.75Dec 2, 25$37.27Dec 4, 25$42.60Dec 8, 25$41.46Dec 10, 25$38.61Dec 12, 25$38.86Dec 16, 25$40.35Dec 18, 25$40.62Dec 22, 25$41.98Dec 24, 25$42.08Dec 29, 25$40.55Jan 2, 26$39.77Jan 6, 26$38.37Jan 8, 26$38.95Jan 12, 26$40.19Jan 14, 26$41.11Jan 16, 26$40.77Jan 21, 26$43.70Jan 23, 26$44.27Jan 27, 26$45.34Jan 29, 26$45.00Feb 2, 26$46.53Feb 4, 26$48.14Feb 9, 26$47.71Feb 11, 26$47.22Feb 13, 26$46.01Feb 18, 26$45.08Feb 20, 26$44.22Feb 24, 26$45.30Feb 26, 26$45.84Mar 2, 26$45.61Mar 4, 26$46.48Mar 6, 26$44.83Mar 10, 26$51.06Mar 12, 26$51.84Mar 17, 26$50.39Mar 19, 26$49.43Mar 23, 26$49.00Mar 25, 26$31.73Mar 27, 26$30.38Mar 31, 26$29.85Apr 2, 26$28.71Apr 7, 26$28.33Apr 9, 26$27.88Apr 13, 26$27.42Apr 15, 26$26.85Apr 17, 26$28.09Apr 22, 26$26.50Apr 24, 26$25.81Apr 28, 26$25.95Apr 30, 26$26.58May 4, 26$26.93May 6, 26$26.47May 8, 26$26.03May 12, 26$25.78May 14, 26$26.43May 18, 26$24.50May 20, 26$25.03May 22, 26$25.78May 28, 26$26.40Jun 1, 26$25.46Jun 3, 26$24.86Jun 5, 26$24.27Jun 9, 26$23.93Jun 11, 26$24.09Jun 15, 26$24.27Jun 17, 26$24.84Jun 22, 26$25.57Jun 24, 26$26.67Jun 26, 26$28.43Jul 2, 26$31.26
$12.1252-week range$51.84
Loading valuation history…

Fundamentals

Key fundamentals

$1.5B

Market cap

—

Revenue growth (YoY)

100.0%

Gross margin

-$112.7M

Free cash flow (USD)

-$318.6M

Net debt

Net cash position

-1.9%

Share dilution

1/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2022 → 2025

FY 2022$0.00FY 2023$0.00FY 2024$167.5MFY 2025$0.00
$0$0

Free cash flow by year

2022 → 2025

FY 2022$-101.2MFY 2023$-87.3MFY 2024$74.8MFY 2025$-112.7M
-$101.2M-$112.7M

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

10

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $1.0M · 10b5-1 PlanColoma Jason V · Director, Chief Executive Officer · $1MJul 2, 2026Filing
  • Insider sellInsider Sell $210K · 10b5-1 PlanDandekar Atul · CSBO · $210.2KJul 1, 2026Filing
  • Insider sellInsider Sell $725K · 10b5-1 PlanColoma Jason V · Director, Chief Executive Officer · $725.5KJun 24, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 10, 2026Filing
  • Insider sellInsider Sell $381K · 10b5-1 PlanBernstein Harold · President, R&D & CMO · $381.1KJun 3, 2026Filing
  • Insider sellInsider Sell $174K · 10b5-1 PlanColoma Jason V · Director, Chief Executive Officer · $174KJun 3, 2026Filing
  • Insider sellInsider Sell $198K · 10b5-1 PlanDandekar Atul · CSBO · $197.6KJun 2, 2026Filing
  • Insider sellInsider Sell $847K · 10b5-1 PlanColoma Jason V · Director, Chief Executive Officer · $847KMay 27, 2026Filing
  • 8-K eventExecutive ResignationMay 22, 2026Filing
  • Insider sellInsider Sell $393K · 10b5-1 PlanBernstein Harold · President, R&D & CMO · $393.4KMay 18, 2026Filing

Questions

Frequently asked questions

What is Maze Therapeutics, Inc.'s market cap?

Maze Therapeutics, Inc. (MAZE) has a market capitalization of $1.5B.

What is MAZE's P/E ratio?

A meaningful P/E ratio is not available for MAZE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is MAZE's price-to-book (P/B) ratio?

MAZE trades at 4.15 times book value per share.

Are insiders buying MAZE stock?

SEC Form 4 filings show no open-market insider buys at Maze Therapeutics, Inc. in the last 90 days (10 sells).

Same arena

Related companies in Biotechnology

TSHA

Taysha Gene Therapies, Inc.

$1.5B

IMCR

Immunocore Holdings plc

$1.5B

FTRE

Fortrea Holdings Inc.

$1.5B

ARDX

Ardelyx, Inc.

$1.5B

IOVA

Iovance Biotherapeutics, Inc.

$1.4B

INBX

Inhibrx Biosciences, Inc.

$1.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.